MORE►
taysha
[Source image: istockphoto]
Taysha Gene Therapies Raises $150M for Its Rare Disease Drug Pipeline
by Lance Murray | Aug 16, 2023
Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.
by Lance Murray |
Feb 13, 2023
The new two-story lab and office building will offer "the first institutional-quality space" in the DFW market, according to marketing materials.
MORE►
by Alex Edwards |
Apr 12, 2021
Taysha Gene Therapies, which rocketed from a UTSW spinout to a $157 million IPO in under six months last year, has gone global with rights to TSHA-120, a promising AAV9 clinical-stage gene therapy.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
MORE►
by Quincy Preston |
Feb 26, 2021
In under six months, Taysha Gene Therapies rocketed from the unveiling of its UTSW spinout to a $157 million initial public offering. We talk with Founder and CEO R.A. Session II about the biotech with big plans.
MORE►
Riding the Funding Wave: These DFW Startups Got the Money in 2020
by Quincy Preston and Sandra Engelland | Feb 11, 2021
Here are 32 North Texas startups that successfully pulled in capital to back their ventures.
Fitting the digital demands of a global pandemic, it's a tech-heavy group, with liberal doses of biotech and healthcare-related firms.
MORE►
by Alex Edwards |
Jan 13, 2021
The expanded alliance between Taysha and UTSW, which dates back to when Taysha emerged from stealth in April 2020, will support the discovery of novel gene therapy candidates and technologies in new disease areas.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Quincy Preston and Alex Edwards |
Aug 5, 2020
Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.
MORE►
